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Abstract
Introduction: Comprehensive approaches for patients with psychotic symptoms play essential roles in the
symptomatic and functional outcomes of patients, especially during disease onset. In Japan, the shortage of mental
health services, particularly for outpatients, and community-based supports has been a major problem. The
purpose of this trial is to investigate the effectiveness and affordability of 18-month comprehensive early
intervention services for patients with first-episode psychosis compared with typical treatment.
Methods: This interventional, parallel, single-blinded (open but blinded raters trial) was effectively designed. The
participants are patients with a diagnosis of F2 or F3 (International Classification of Disease, 10 th revision), with
psychotic symptoms. The inclusion criteria were an age of 15-35 years, onset of psychotic symptoms within 5
years, first-episode psychosis, and residence in the catchment area of each site. Allocation will be conducted
equally between case management and standard care groups. After enrollment, standard care will be provided for
both groups, and community-based care to promote recovery for 18 months will be provided for the
comprehensive approach group. The primary outcome will be the function domain of the global assessment of
functioning scores at 18 months after enrollment. Data assessment will be performed at enrollment and 18, 36,
and 60 months after enrollment. The target sample size will be 150, and registration will occur from March 1, 2011,
to September 30, 2012.
Discussion: This trial will provide promising results about the effectiveness and cost-effectiveness of early
intervention services in Japan to improve the quality and quantity of community mental health services.
Trial registration: This trial was registered in The University Hospital Medical Information Network Clinical Trials
Registry (No. UMIN000005092).
Introduction
Comprehensive approaches for patients with schizophre-
nia play essential roles in their symptomatic and func-
tional outcomes[1-4]. Particularly after the onset of
psychosis, most patients and their families are extremely
confused and distressed because of the conditions of
patients and the lack of knowledge about their illnesses.
Several randomized controlled trials (RCTs) have
suggested that intensive community-based care for
patients with first-episode psychosis (FEP) improve
patient symptoms[5,6] and functional outcomes such as
relapse, readmission, dropout from services, and social
and vocational functioning[5-8]. Furthermore, additional
analyses of cost-effectiveness revealed that patients with
FEP who received intensive care had better outcomes
without increase costs[9]. On the basis of these results,
the use of early intervention services (EIS) has increased,
especially in England[1].
Japan has among the best medical services in the
world (e.g., the longest average life expectancy and smal-
lest perinatal mortality rate). However, the shortage of
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mental health services for outpatients has been a major
problem. In Japan, there are approximately 350,000 psy-
chiatric beds, and approximately 210,000 patients
majorly diagnosed with schizophrenia remain in psy-
chiatric hospitals for more than 1 year (Reported from
the Minster of Health, Labour, and Welfare). One issue
preventing the discharge of patients with severe mental
illnesses from hospitals is the shortage of community
mental health services with psychosocial approaches,
including family support despite the vast medical
resources of Japan[10]. To change this situation and
broaden EIS based on community settings, an RCT is
needed to confirm the clinical effectiveness and afford-
ability of EIS compared with existing hospital-based
mental health service systems in Japan. Additionally,
these trials must examine whether these specialized
community mental health services will sustain the func-




This trial is designed with effectiveness, interventional,
parallel, single-blinded (open but blinded raters) trial.
The allocation of participants will be equal (1:1)
between the comprehensive approach (CAP) and stan-
dard care (SC) groups. The entire trial design is illu-
strated in Figure 1. After enrollment, all participants will
be provided standard care, and in the CAP group, com-
prehensive community-based care by an early interven-
tion team will be provided for 18 months. Eighteen
months after enrollment, all participants will be pro-
vided standard care only. The assessment of clinical
data will be conducted at enrollment and 18 (first end
point), 36 (second end point), and 60 months after
enrollment (last end point). The target sample size will
be 150, and registration will occur from March 1, 2011,
to September 30, 2012. The last follow-up date will be
September 30, 2017. This trial was registered in the Uni-
versity Hospital Medical Information Network Clinical
Trials Registry (UMIN-CTR) accepted from the Interna-
tional Committee of Medical Journal Editors (ICMJE)
(No. UMIN000005092).
Participants
The participants are patients who received a diagnosis of
F2 or F3 (International Classification of Disease, 10 th
revision)[11], with psychotic symptoms, at 4 sites: the
University of Tokyo Hospital, Tokyo Metropolitan Mat-
suzawa Hospital, Mie Prefectural Mental Medical Cen-
ter, and Hinaga General Center for Mental Care and
Sasagawa Clinic. The relevant details of the sites are
summarized in Table 1.
Eligibility criteria are summarized in Table 2. The
inclusion criteria are an age of 15-35 years old, onset
of psychotic symptoms within 5 years, first-episode
psychosis, and residence in the catchment area of each
site (Table 1). Psychotic symptoms are defined by the
first clear evidence of a positive psychotic symptom
(i.e., delusion, hallucination, or thought disorder) that
was scored 4 or higher on the positive and negative
symptom scales (PANSS) [12] regardless of its
duration.
Exclusion criteria are premorbid IQ [13,14] of less
than 80, inability to sufficiently communicate in Japa-
nese, requirement of care for any organic mental disor-
der or inpatient care for any physical condition, a
history of dependency on alcohol and/or other sub-
stance of abuse, under physical restraint and/or seclu-
sion, received electroconvulsive therapy and/or
transcranial magnetic stimulation therapy within the
past month, present involuntary hospitalization, not hav-
ing been given the explanation of his or her condition
or diagnosis from a psychiatrist, and being regarded as
inappropriate by their doctors for any other reason.
Although the use of illegal substances such as cannabis
among young people has been a major problem, a very
small number of young people have used these drugs in
Japan. Therefore, we adopted a history of continuous
substance abuse as one of the exclusion criteria in this
trial.
All of the eligibility criteria will be assessed by psy-
chiatrists at each site; to complement these criteria, the
laboratory data of all patients will be assessed within 30
days of enrollment, and a brain CT or MRI will be per-
formed within 12 months.
Ethical consideration
All participants will be presented with written informed
consent to the ethical committee of each site (Univesity
of Tokyo, No. 3307; Matsuzawa, No. 22-23; Mie,
H23.2.21; Hinaga, H22.12.22) according to the Declara-






















Figure 1 Entire design of this trial.
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Table 1 Characteristics of facilities, number of patients, and number of staff members on early intervention teams at
each site
Univ of Tokyo Matsuzawa Mie Hinaga
Beds in closed wards 29 713 200 255
Beds in open wards 31 149 200 300
Annual Total 1107 2150 896 706
hospital 15-35 years
old
381 445 165 184
admissions F2 129 212 55 94
Average number of daily
patients the in outpatient unit
170 329.4 214.2 309.8
Average number of daily
participants in the outpatient
rehabilitation center
33.1 57.6 49.9 109.6
Annual new
patients
Total 1102 5656 1405 1150
15-35 years
old
474 NA 476 450
F2 124 NA 43 58
Catchment area Bunkyo, Arakawa,
Taito, and Chiyoda
Setagaya, Suginami, Ota, Meguro,
Shibuya, Komae, Chofu, and Mitaka
Tsu, Matsuzaka, Suzuka,
Iga, Nabari, and Ise
Yokkaichi, Suzuka,
Kameyama, and Mie-gun
Population (× 1000) 800 3020 870 620
Psychiatrists 6 5 1 3
Nurses 0 4 5 6





1 2 3 2
Vocational
workers
0 0 1 1
Pharmacist 0 0 1 0
Abbreviations: Univ of Tokyo, the University of Tokyo Hospital; Matsuzawa, Tokyo Metropolitan Matsuzawa Hospital; Mie, Mie Prefectural Mental Medical Center;
Hinaga, Hinaga General Center for Mental Care and Sasagawa Clinic; EIS, early intervention service.
Table 2 Summary of eligibility criteria
Inclusion criteria:
1. Residence in the catchment area of each site (also see Table 1)
2. Age between 15 and 35 years old
3. Within 5 years of the onset of psychotic symptoms
4. FEP
Exclusion criteria:
1. Premorbid IQ below 80
2. Unable to sufficiently communicate in Japanese
3. Require care for any organic mental disorder
4. Require inpatient care for any physical condition
5. A history of dependency on alcohol and/or other substance of abuse
6. Under physical restraint and/or seclusion
7. Received electroconvulsive therapy and/or transcranial magnetic stimulation therapy within the past month
8. Present involuntary hospitalization
9. Not having received an explanation of his or her condition or diagnosis by a psychiatrist
10. Regarded as inappropriate by medical doctors in charge for any other reason
Target patients: Patients with a diagnosis of F2 and F3 (International Classification of Disease, 10 th revision), with psychotic symptoms.
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Intervention
For the CAP group, we will provide specialized early
intervention teams by well-trained case managers and
psychiatrists about their symptoms and daily activities
for 18 months after enrollment. Case managers will pro-
mote participant recovery and social participation in
cooperation with the early intervention team by using
combination of cognitive behavioral therapeutic (CBT)
approaches, psychoeducational approaches, family inter-
ventions, discharge support, and pharmacological ther-
apy in accordance with the guidelines for FEP. The
details of comprehensive community-based care are
described later in the text. After 18 months, the partici-
pants will receive only standard care at each site. For
the SC group, we will provide only standard care at
each site throughout the entire study.
CBT approach
Several researches have suggested that CBT adapted to
patients with early psychosis has effectiveness regarding
their persistent positive symptoms, anxiety, and/or
depression[15]. In this trial, we will not adopt structured
CBT but needs-based CBT approaches in comprehen-
sive community-based care. Case managers will receive
basic CBT training and use the skills and techniques of
CBT in comprehensive community-based care. The
range and intensity of CBT will vary according to parti-
cipant need as assessed by the early intervention team.
Through CBT sessions, case managers will provide
monitoring and coping skills for patients regarding their
symptoms as well as functional skills for their daily lives.
Psychoeducational approach
Young people and their families rarely learn about
symptoms, outcomes, and methods of coping with psy-
chosis until they have mental illnesses; in other cases,
they received incorrect information in addition to being
subjected to discrimination and stigma. Therefore, they
have significant stress and confusion because of the lack
of information about psychosis. Several studies have
suggested that psychoeducation is effective for relapse
prevention, reducing hospital admission, and adherence
of medication[16-18]. In this trial, the psychoeducational
program for people with FEP will consist of sessions
that provide not only information about etiology, symp-
toms, treatments, and outcome of psychosis, but also
positive and helpful information toward functional
recovery. In addition, we will provide psychoeducational
programs for their families as described in the following
section.
Family intervention
Family interventions will consist of 2 main domains of
psychoeducation and family support for the family
members of patients with mental illnesses. As described
above, family members usually have little correct knowl-
edge but a plethora of incorrect information and a great
deal of stigma. Therefore, family members are also con-
fused about methods of assisting patients who have
recently exhibited psychotic symptoms. Several studies
have suggested that family intervention for early psycho-
sis is effective for relapse prevention, reducing hospital
admission, and adherence of medication[19-21]. Family
interventions for early psychosis will consist of psychoe-
ducational programs and psychological therapy or coun-
seling for families to relieve their burdens regarding the
care of people with psychosis. Psychoeducational pro-
grams for families will consist of lectures about psycho-
sis and peer group sessions. Psychological therapy and
counseling for families will be provided through indivi-
dual sessions.
Discharge support
More than 210,000 patients with schizophrenia stay in
hospital for more than 1 year in Japan, mainly because
of a lack of community mental health services[10]. This
is particularly true for patients with psychosis for whom
their family members are unable to obtain information
and support from psychiatric community services. In
this trial, case managers will encourage patients to live
in their communities by introducing additional psychia-
tric community services, if needed.
Pharmacological therapy in accordance with the guidelines
for FEP
Several pharmacological guidelines for schizophrenia
and mood disorder are available worldwide. However,
some psychiatrists in Japan have developed experi-
mence-oriented strategies that result in polypharmacy
for patients with schizophrenia[22]. Polypharmacy can
exacerbate the negative symptoms and cognitive
impairments of patients in addition to promoting
dropped-out from treatment[22]. One reason why psy-
chiatrists tend to prescribe more tablets may be that
patients’ treatment strategy and prescription are mainly
decided by their psychiatrists who know little informa-
tion except from the consultation with patients and
their family members. In this trial, we will conduct
regular meetings with early intervention teams and
propose treatment and prescription strategies to psy-
chiatrists according to the guidelines to eliminate
unnecessary prescriptions.
Strategy for replacement from EIS
Recent studies about EIS for patients with FEP had
negative results regarding the effectiveness of EIS dis-
continued in a longer term[23,24]. One reason may be
that it is difficult to prepare patients to finish EIS and
switch to normal services. On the basis of this result, we
will emphasize “graduating from the EIS” and provide
the policy of EI services to switch over to usual commu-
nity services in order to easily maintain the effectives of
EIS. Thus, we will also investigate whether this strategy
for switch over will prolong the effectiveness of EIS.
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Supervision for case management
To standardize the intensity and quality of EIS, we will
conduct training courses at least twice a year with
required participation by case managers at each site, at
which they will have to discuss their practices and cases.
Supervision in meetings will be provided, and profes-
sionals and supervisors of other services will discuss and
provide advice about their practices and cases.
Outcomes and measurement items
We will adopt the function domain of the global assess-
ment of functioning (GAF-F) [25] scores at the first end
point as the primary outcome measure. Secondary out-
comes will be GAF-F at the second and last end points,
symptom domain of global assessment of functioning
(GAF-S), PANSS,[12] the World Health Organization
quality of life 26-item version (WHO-QOL26),[26,27]
brief evaluation of medication influences and beliefs
(BEMIB),[28] care satisfaction of participants and their
families, educational and vocational recovery rates,
remission rate, re-admission rate, lost to follow-up rate,
self-harm and suicide attempt rate, suicide rate, engage-
ment behavior, and direct and indirect costs at each end
point. All measurement items will also be assessed at
baseline. We will record the presence of comorbid men-
tal and physical disorders and relevant sociodemographic
and clinical information about the participants and their
families at baseline and at each end point. The details of
the assessments are discussed in the following sections.
GAF, GAF-F, and GAF-S
GAF records the current objective symptomatic and
functional conditions of participants on one analogous
scale ranging from 0 (poor) to 100 (good)[25]. GAF-F
rates the social and occupational functions of patients,
and GAF-S rates their symptoms. GAF is adopted as the
worse score of GAF-F and GAF-S. We will also use the
modified GAF scale [29] to measure GAF, GAF-F, and
GAF-S.
PANSS
PANSS records the current objective symptoms of
patients on 30 items[12]. PANSS consists of 3 domains:
positive symptoms, negative symptoms, and general psy-
chopathology. Each item is rated from 1 (absent) to 7
(extreme), and the total score ranges from 30 to 210.
WHO-QOL26
WHO-QOL26 [26,27] measures the current subjective
satisfaction of participants regarding their quality of life
on 26 items. WHO-QOL26 consists of 4 domains: phy-
sical health, psychological health, social relationships,
and environment. Each item is rated from 1 (poor) to 5
(good) and presented as an average score.
BEMIB
BEMIB measures the current drug adherence of partici-
pants to their medications on 8 items[28]. Each item is
rated from 1 (completely disagree) to 5 (completely
agree), and the total score ranges from 8 to 40.
Care satisfaction
Care satisfaction will be measured by one simple item
rated from 1 (very satisfied) to 4 (very dissatisfied). Par-
ticipants and their families will provide subjective care
satisfaction ratings after enrollment.
Recovery rate
Recovery will be measured by using the definition sheet
adopted for EIS in England[30]. The item in the sheet
termed “TRAINING AND OCCUPATION,” which is
rated from 0 (employment) to 4 (Not in Education,
Employment or Training; NEET), will be assessed. For
the initial assessment, this rating will be taken from the
best occupational status achieved within the last 6
months for each end point taken from the point of last
assessment.
Remission rate
We defined remission using a proposal from the Remis-
sion in Schizophrenia Working Group [31] that defined
symptomatic remission of illness using 8 corresponding
PANSS subscores (P1, P2, P3, N1, N4, N6, G5, and G9)
of mild or less simultaneously on all items and for
which remission regarding these scores was maintained
for at least 6 months.
Re-admission rate
We will record all voluntary and involuntary admissions
of participants at registration and during the follow-up
period.
Lost to follow-up rate
Lost to follow-up will be defined at each end point as
the refusal of further treatment despite the need and
several attempts of reengagement (phone calls to
patients and families in both groups and home visits to
participants in the CAP group)[32]. We will consider
the last successful contact the date of lost to follow-up.
Self-harm, suicide attempt, and suicide rate
Self-harm and suicide attempt will be measured using
the items in the definition sheet “SELF-HARM and SUI-
CIDE” on a scale of 0 (None) to 4 (Severe problems)
[30]. We will assess the inquiry sheets for all of the sui-
cide and severe self-harm actions at all sites.
Engagement behavior
Engagement, family engagement, and social relationships
will be measured using the items in the definition sheet
“ENGAGEMENT, FAMILY/CARER ENGAGEMENT,
and RELATIONSHIPS” on a scale of 0 (Severe pro-
blems) to 4 (Very good) [30].
Service costs and cost-effectiveness
Service costs will be calculated using the Client Service
Receipt Inventory (CSRI),[9,33], which can estimate ser-
vice costs and cost-effectiveness, particularly in psychia-
tric contexts. On the basis of the CSRI, we will conduct
interviews of daily living (e.g., service use, school,
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employment, and family conditions) at registration, at
each end point, and if possible, at intermediate points
between end points. Service costs will be calculated by
the service costs and appropriate local unit costs. Cost-
effectiveness will be calculated by the combination of
the outcomes related to the service costs and participant
subjective quality of life assessments using WHO-
QOL26. Unavailable cost data will be estimated using
other resources and models.
Data reliability
Some methodological problems regarding interrater
reliability will exist. To control the quality of data
assessment, we will conduct lectures for PANSS and
GAF, including GAF-F and GAF-S, more than once a
year using video movies to ensure accurate scoring. We
will also calculate interrater reliability for PANSS and
GAF scores provided by the raters in the lecture, and
we will provide feedback for these results to maintain a
high quality of assessment.
Sample size
The planned number of participants is 150, as deter-
mined by previous RCT results, the clustering effects of
each site, and the possibility of exhaustion of our
resources. An RCT of EIS for patients with FEP in Hol-
land indicated that EIS improved participant GAF-F
scores in 24 months[5]. Another RCT of CBT in Eng-
land revealed that CBT improved patient readmission
rates and GAF scores in 18 months[6,7]. The effect sizes
calculated from their results were 0.26, 0.46, and 0.58,
respectively. The estimated sample sizes using G*Power
3[34] (alpha error = 0.05, beta error = 0.2) were 370,
150, and 96, respectively.
We will adopt 1 interim analysis and consider stop-
ping the trial if the participants in the CAP group have
unexpected effective outcomes compared with those in
the SC group. We will conduct the interim analysis
when half of the participants finish the trials until the
first end point. Stopping rules will be planned on the
basis of the O’Brien-Fleming method [35] for the GAF-F
score, re-admission rate, lost to follow-up rate, self-
harm and suicide attempt rate, and suicide rate at the
first end point. We will consider stopping the trial on
the basis of the stopping rule, baseline data, missing
data, and site. Because of ethical issues, we will provide
EIS to all participants until 18 months after allocation if
the trial is halted.
Randomization
Enrollment and random allocation will be performed by
central registration at the University Hospital Clinical
Trial Alliance Clinical Research Supporting System
(UHCT ACReSS) at the University of Tokyo. The
managers of each site will enroll participants after exam-
ining their eligibility and informed consent. The type of
allocation will be stratified and block randomization.
We will adopt stratification as sites and inpatients/out-
patients at enrollment. Owing to allocation concealment,
the block size will be provided by UHCT ACReSS and
will not be revealed to any researchers or staff until the
end of the enrollment period. As this is a single-blinded
trial, all assessments after enrollment will be conducted
by independent raters with no knowledge of any treat-
ment and care provided this trial.
Statistical method
All findings will be reported according to the revised
CONSORT statement[36]. All analyses will be per-
formed using SPSS 17.0 J (SPSS Inc., Chicago, IL, USA).
All data will be analyzed under the intent-to-treat prin-
ciple. The primary outcome will be analyzed using a
simple Student’s t test and analyzed regarding potential
confounders (e.g., age, gender, sociodemographic factors,
site, and clinical characteristics) using regression models.
Secondary outcomes will be analyzed using relevant
tests at each end point and for possible confounders as
described for the primary outcome. Subgroup analysis
will be conducted at sites and performed for any possi-
ble confounders to differentiate the effectiveness of each
situation and explore cluster effects.
Discussion
This trial has some possible limitations regarding sample
size and the duration of case management. Previous stu-
dies of EIS for patients with FEP have suggested that
although 1.5-year EIS improved patient social functions
and readmission rates, these effects did not persist (5
years)[23,24]. However, these results also depend on the
treatment provided to the control group, and commu-
nity mental health services are widely available in Hol-
land and England[1]. In the present situation in Japan,
little psychological education is provided in schools and
the workplace, and few mental health services are avail-
able in the community setting; consequently, much pre-
judice, discrimination, and stigma exists regarding
psychosis[10]. In addition, we will emphasize “graduat-
ing from the service” in that case managers will con-
tinue to provide services after EIS after a participant
enrolls in the trial. Therefore, this trial will demonstrate
the effectiveness of EIS in Japan and also explore and
consider exit strategies for EIS. Finally, the results of
this trial will be used to inform policy makers and prac-
titioners about the benefits, required human resources,
and cost-effectiveness of EIS. This trial will provide
helpful results about the effectiveness and cost-effective-
ness of EIS in Japan to improve the quality and quantity
of community mental services.
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